Case Report
Published on 09 Jan 2023
Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
in Breast Cancer
Frontiers in Oncology
doi 10.3389/fonc.2022.1022913
- 4,556 views
- 1 citation

